The Journal of Urology
Volume 175, Issue 5 , Pages 1673-1678 , May 2006

Intermittent Use of Testosterone Inactivating Pharmaceuticals Using Finasteride Prolongs the Time Off Period

Presented at annual meeting of American Urological Association, Dallas, Texas, May 1-6, 1999.

Received 17 June 2005

References 

  1. Akakura K , Bruchovsky N , Goldenberg SL , Rennie PS , Buckley AR , Sullivan LD , et al.   Effects of intermittent androgen suppression on androgen-dependent tumors (apoptosis and serum prostate-specific antigen) . Cancer . 1993;71:2782
  2. Schasfoort E , Heathcote P , Lock T , Zerbib M , Dijkema M , Vergunst H , et al.   Intermittent androgen suppression for the treatment of advanced prostate cancer . J Urol . 2003;169(suppl):1483; 397
  3. Tunn UW , Eckart O , Offenbach DE , Kienle EF , Hillger H , Aachen DE . Can intermittent androgen deprivation be an alternative to continuous androgen withdrawal in patients with PSA relapse? First results of the randomized prospective phase-III clinical trial EC 507 . J Urol . 2003;169(suppl.):396; abstract 1481
  4. Andriole G , Lieber M , Smith J , Soloway M , Schroeder F , Kadmon D , et al.   Treatment with finasteride following radical prostatectomy for prostate cancer . Urology . 1995;45:491
  5. Kirby R , Robertson C , Turkes A , Griffiths K , Denis LJ , Boyle P , et al.  International Prostate Health Council (IPHC) Trial Study Group   Finasteride in association with either flutamide or goserelin as combination hormonal therapy in patients with stage M1 carcinoma of the prostate gland . Prostate . 1999;40:105
  6. Kaplan SA , Ghafar MA , Volpe MA , Lam JS , Fromer D , Te AE , et al.   PSA response to finasteride challenge in men with a serum PSA greater than 4 ng/ml and previous negative prostate biopsy (preliminary study) . Urology . 2002;60:464
  7. Tay MH , Kaufman DS , Regan MM , Leibowitz SB , George DJ , Febbo PG , et al.   Finasteride and bicalutamide as primary hormonal therapy in patients with advanced adenocarcinoma of the prostate . Ann Oncol . 2004;15:974
  8. Thompson IM , Goodman PJ , Tangen CM , Tangen CM , Lucia MS , Parnes HL , et al.   The influence of finasteride on the development of prostate cancer . N Engl J Med . 2003;349:215
  9. Scardino PT . The prevention of prostate cancer-the dilemma continues . N Engl J Med . 2003;349:297
  10. Bostwick DG , Qian J , Civantos F , Roehrborn CG , Montironi R . Does finasteride alter the pathology of the prostate and cancer grading? . Clin Prostate Cancer . 2004;2:228
  11. Carver SC , Kattan MW , Scardino PT , Eastham JA . Gleason grade remains an important prognostic predictor in men diagnosed with prostate cancer while on finasteride therapy . BJU Int . 2005;95:509
  12. Al-Azub KR , Lockwood G , Toi A , Jewett MA , Trachtenberg J , Fleshner N . Evidence for a biopsy-derived grade artifact among larger prostate glands (implications for the prostate cancer prevention trial) . J Urol . 2005;173(suppl.):70; abstract 254
  13. Roehrborn CG . Letter to the editor (prevention of prostate cancer with finasteride) . New Engl J Med . 2003;349:1569
  14. Andriole GL , Guess HA , Epstein JI , Wise H , Kadmon D , Crawford ED , et al.  PLESS Study Group. Proscar Long-term Efficacy and Safety Study   Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer (results of a randomized, double-blind, placebo-controlled clinical trial) . Urology . 1998;52:195
  15. Scholz MC , Trilling T , Brosman SA , Guess BW , Johnson HJ , Lam RY . PSA nadir greater than 0.1 on combined hormone blockade predicts the early development of androgen independent prostate cancer in men with PSA relapse after local therapy . Presented at meeting of Western Section, American Urological Association . 2003; abstract 09-43
  16. Nejat RJ , Rashid HH , Bagiella E , Katz AE , Benson MC . A prospective analysis of time to normalization of serum testosterone after withdrawal of androgen deprivation therapy . J Urol . 2000;164:1891
  17. Pickles T , Agranovich A , Berthelet E , Duncan GG , Keyes M , Kwan W , et al.   Testosterone recovery following prolonged adjuvant androgen ablation for prostate carcinoma . Cancer . 2002;94:362
  18. De La Taille A , Zerbib M , Conquy S , Amsellem-Ouazana D , Thiounn N , Flam TA , et al.   Intermittent androgen suppression in patients with prostate cancer . BJU Int . 2003;91:18
  19. Sato N , Akakura K , Isaka S , Nakatsu H , Tanaka M , Ito H , et al.   Intermittent androgen suppression for locally advanced and metastatic prostate cancer (preliminary report of a prospective multicenter study) . Urology . 2004;64:341
  20. Wessells H , Roy J , Bannow J , Grayhack J , Matsumoto AM , Tenover L , et al.   Incidence and severity of sexual adverse experiences in finasteride and placebo-treated men with benign prostatic hyperplasia . Urology . 2003;61:579

PII: S0022-5347(05)00975-4

doi: 10.1016/S0022-5347(05)00975-4

The Journal of Urology
Volume 175, Issue 5 , Pages 1673-1678 , May 2006

Article Tools

* Image Usage & Resolution